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Abstract: To increase understanding of the epi-
demiology, risks, consequences and resource
utilization of Clostridium difficile infection (CDI)
in Japan, a systematic literature review was
undertaken of relevant publications from Jan-
uary 2006 to November 2017. Using the Pre-
ferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines and
methods, 55 articles met the criteria for full
review. The majority (58%) of studies were from
a single site, with the most recent data from
2015. The incidence, reported prevalence and
recurrence rate of CDI in Japan were 0.8–4.71/
10,000 patient-days, 0.3–5.5/1000 patients and
3.3–27.3%, respectively, and varied according to
setting, population, CDI definition and detec-
tion method. Most C. difficile isolates associated
with CDI in Japan were toxin A?B?, with a low
level of C. difficile binary toxin-positive (CDT?)
strains (0–6.8% reported across studies). The
most common C. difficile PCR ribotypes associ-
ated with infection in Japan were smz/018, 002,
052 and 369. Data regarding the impact of CDI
on length of hospital stay were limited. Reported
all-cause mortality in patients with CDI ranged
from 3.4 to 15.1% between 2007 and 2013. Two
studies assessed risk factors for CDI recurrence,
identifying malignant disease, intensive care
unit hospitalization and use of proton pump
inhibitors as factors increasing the risk of initial
and/or recurrent CDI. No study analyzed initial
CDI treatment in relation to recurrence. More
comprehensive surveillance and coordinated
studies are needed to map trends, understand
risk factors, and recognize the extent and impact
of CDI in Japanese patients.
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people’s gut. However, when a person has
antibiotic treatment for another infection, this
can cause an imbalance in the normal levels of
bacteria in the gut, and the C. difficile can grow
and replace many of the normal bacteria, caus-
ing C. difficile infection (CDI). Symptoms
include diarrhea, fever and pain. Although CDI
is often mild, it can be very serious, particularly
in older people, and, if untreated, can be fatal.
This review looked at studies published from
2006 to 2017 to investigate patterns of CDI
sickness (epidemiology) in Japan. A total of 55
studies were useful for our review and showed
that, in general, CDI occurred less commonly in
Japan than in Western countries. However,
there was wide variation in the tests used to
detect infection and the methods used to
identify specific types of C. difficile bacteria
responsible for the infections. Because of this
variety, there was a difference in the reliability
of the results from the different studies, which
made it difficult to make comparisons between
studies. However, there seemed to be consistent
results showing that certain types of C. difficile
were common in Japan. The studies were not
able to tell us whether the types of C. difficile
varied over time. More studies that use reliable
high-quality tests, and greater detailed analysis
in Japan to map patterns of CDI over time are
needed. This would help us to understand the
importance of CDI in Japan.
INTRODUCTION
Clostridium difficile is the most common infec-
tive cause of nosocomial diarrhea, implicated in
20–30% of cases of antibiotic-associated diar-
rhea [1, 2]. Appropriate patient care requires
rapid and accurate diagnosis to support optimal
management and prevent the spread of infec-
tion. Furthermore, knowledge of specific risk
factors for C. difficile infection (CDI) in different
clinical settings is essential.
No national CDI surveillance system has
been implemented in Japan, and therefore it is
challenging to grasp the trend in epidemiology
over time using a standardized method. A
review of CDI in Asia published in 2013 found
only a few molecular-typing studies providing
contemporary epidemiological information [3].
According to a questionnaire-based survey of
2537 hospitals in Japan in 2013, which had
valid responses from 321 hospitals, CDI inci-
dence varied between centers [4], and there was
little information on the specific strains causing
infection.
There have been several important changes
in CDI diagnosis and treatment in Japan. First,
a new diagnostic kit detecting toxin A and B
plus ‘‘common’’ antigen (glutamate dehydro-
genase; GDH) became available in April 2011.
Second, oral and injectable metronidazole were
indicated for CDI in August 2012 [5] and
September 2014 [6], respectively, although
unlicensed use of oral metronidazole for CDI
had occurred in Japan prior to 2012. Third, in
2015, the Japanese Association for Infectious
Diseases and Japanese Society of Chemother-
apy released guidelines for the treatment of
enteric infection, in which oral metronidazole
was designated as the first-line treatment for
CDI [7]. Vancomycin was recommended for
severe cases and/or second and subsequent
recurrences [7].
Considering these recent changes in the
diagnosis and treatment of CDI, there is a
greater need to understand and update the
epidemiology of CDI, the predominant strains
causing the infection, and the consequences,
risks and resource utilization associated with
CDI in clinical settings in Japan. This literature
review was undertaken to summarize published
epidemiological data on CDI in Japan from
January 2006 to November 2017, to describe
definitions of CDI applied, molecular typing
and diagnostic methods used, and key risk fac-
tors and expected outcomes.
METHODS
The recent literature was reviewed in a system-
atic fashion to identify studies and reports
relating to the epidemiology of CDI in Japan.
The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines
were used to inform search terms, and the lit-
erature review process was conducted using the
PRISMA Checklist and PRISMA Flow diagram.
40 Infect Dis Ther (2018) 7:39–70
Identification
Searches of MEDLINE-PubMed and EMBASEwere
made using the following primary search terms:C.
difficile infection; pseudomembranous colitis; epi-
demiology; Japan. Secondary search terms were as
follows: C. difficile diarrhea; C. difficile colitis;
enterocolitis; toxic megacolon; hospital-acquired
diarrhea; nosocomial diarrhea; antibiotic-associ-
ated diarrhea; incidence; Japan. The publications
were limited to the English language from 1 Jan-
uary 2006 to 27 November 2017.
Selection
Identified abstracts were reviewed by a single
reviewer to remove duplicates and to identify
publications meeting the pre-defined inclusion
and exclusion criteria. Inclusion criteria were:
Japanese patients or human samples with CDI;
observational or non-randomized interventional
studies; cross-sectional surveys; cohort studies;
case–control studies; pharmacy records or claims
databases; electronic registers or electronic medi-
cal/health records; insurance or administrative
claims databases studies; registry studies; prospec-
tiveor retrospective studies; longitudinalor follow-
upstudies; andreviews.Publicationswere included
if they reported on: CDI epidemiology (incidence/
prevalence); CDI risk factors; CDI definitions;
diagnostic and laboratory test methods; CDI
strains; length of hospital stay (LOS); intensive care
unit admission; CDI recurrence; and mortality.
There was reliance on the individual publications
to define CDI and no minimum (discriminatory)
definition was used during the selection process.
Exclusion criteria were: animal studies; in vitro
studies; case reports; editorials, commentaries and
letters; congress abstracts; and non-English lan-
guage publications. All publications that met cri-
teria for the review were obtained as full articles,
reassessed and reviewed.
Quality Determination and Data
Extraction
A single reviewer assessed the quality of each
paper/study according to Oxford Centre for Evi-
dence-Based Medicine – Levels of Evidence [8]
(Enhanced Supplementary Material). As most of
the captured studies did not fall strictly within a
given category, references were also assessed by the
same individual to ensure consistent application of
the criteria across all publications.
Data from the selected studies were extracted
by a single reviewer and used to populate sum-
mary tables.
Compliance with Ethics Guidelines
The analysis in this article is based on previ-
ously conducted studies and does not involve
any new studies of human or animal subjects
performed by either of the authors.
RESULTS
Identification of Relevant Publications
A total of 385 potential articles were identified,
of which 55 were defined as relevant, after
Fig. 1 Assessment of search results to identify key papers
for review and data extraction. Asterisk did not meet
inclusion criteria in relation to study population or design
(see ‘‘Selection’’). Hash did not include reports of:
Clostridium difficile infection (CDI) epidemiology (inci-
dence/prevalence); CDI risk factors; CDI definitions;
diagnostic and laboratory test methods; CDI strains;
length of hospital stay; intensive care unit admission; CDI
recurrence; or mortality. Dagger one identified article was
an erratum of a previously identified study, therefore the
study was counted only once
Infect Dis Ther (2018) 7:39–70 41
applying the pre-defined inclusion and exclu-
sion criteria (Fig. 1). One article was an erratum
[9] of a previously identified study [10], there-
fore the study was counted only once. The
assigned grades of literature per relevant article
are summarized in the Enhanced Supplemen-
tary Material.
Many papers were insufficiently specific: for
example, several papers reported on the valida-
tion of novel C. difficile diagnostic assays or
laboratory testing methods in Japan, but did
not include clinical data. Others were excluded
owing to a small sample size (n B 8), a focus on
pre-clinical evaluation of CDI testing methods,
or for reporting CDI contamination in non-pa-
tient groups [11–15]. Several papers were
reviews or editorials with limited relevance to
Japanese CDI epidemiology [3, 16, 17].
Incidence and Prevalence
Twenty-four papers reported data relating to the
incidence and prevalence of CDI, or to C. diffi-
cile-related disease or diarrhea in Japanese
cohorts (Table 1). Most reports were based on
retrospective chart reviews (n = 16), eight were
prospective studies; either observational studies
or randomized controlled trials (RCTs), and one
was a systematic review and meta-analysis. Most
of the papers described and defined CDI in
terms of clinical diagnosis (‘diarrhea’) and lab-
oratory findings (‘toxin positivity’). The papers
differed in their approach to testing for CDI:
some actively investigated C. difficile coloniza-
tion across cohorts whilst others tested for C.
difficile only in patients with clinical symptoms
suggestive of CDI. Testing methods also varied.
Because of these differences and the hetero-
geneity in the patient populations examined in
the publications, including hematopoietic stem
cell transplant (HSCT) patients, rheumatology
patients and those with Helicobacter pylori-posi-
tive peptic ulcer, it was not possible to examine
trends over time in the incidence of CDI.
Very few papers reported incidence in terms
of cases per 10,000 patient-days; most reported
observed CDI ratios (as percentages), with CDI
variously defined, or prevalence within specific
patient subgroups or populations (Table 1).
Figure 2 depicts reported CDI incidence from
retrospective chart reviews in different patient
cohorts, where CDI was defined based on diar-
rhea and laboratory detection of fecal C. difficile
toxin.
A chart review of over 22,800 inpatients at a
single tertiary care center (of whom 851 were
tested for C. difficile) reported on healthcare-fa-
cility onset CDI, defined as diarrhea and a pos-
itive toxin test (using C DIFF QUIK CHEK
COMPLETE) [18]. The CDI prevalence was 5.5
cases/1000 patients. The incidence of health-
care-facility onset CDI was 3.11 cases/10,000
patient-days, compared with 0.2 cases/10,000
patient-days for community-onset CDI [18].
The authors considered the CDI incidence
(hospital- and community-onset) to be rather
low, which they suggested may have been
attributable to the relatively low frequency of
testing for C. difficile and the relatively low
sensitivity of the EIA toxin detection method.
Another large-scale outpatient study (n = 2193)
reported the incidence of community-acquired
CDI as 1.4/100,000 patient-years (or 0.14/
10,000 patient-years) [19], and a study of both
actively tested in- and outpatients provided an
incidence of 0.8 cases/10,000 patient-days [20].
A retrospective cohort study based on chart re-
views at four tertiary care hospitals reported 160
patients aged at least 14 years with hospital-
onset CDI, as defined according to clinical
practice guidelines, giving an incidence of 1.04/
10,000 patient-days (or 1.61/1000 admissions)
[21]. The low incidence of hospital-onset CDI
compared with that reported in studies from
Western countries was suggested by the authors
to be a consequence of the different strains
prevalent in different regions, with outbreaks of
hospital-acquired CDI in Western countries
being attributed to highly virulent strains that
are not prevalent in Japan. The study did not
explore the strains responsible for the CDI epi-
sodes at the four hospitals. The authors also
suggested that the low frequency of CDI may be
a consequence of the low frequency of testing
for C. difficile [21].
Few studies identified in our search described
measures to control the incidence of C. difficile
in hospitals. Although not strictly an infection
control measure, the prophylactic use of pre-
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and probiotics has been suggested to maintain
the colonic microbiota and potentially reduce
the development of CDI [22]. A single-center
RCT of 379 patients undergoing colorectal sur-
gery evaluated the impact of perioperative syn-
biotics (combination of pro- and prebiotics) on
post-surgical outcomes and fecal microbiota
composition, finding that patients administered
synbiotics before surgery had a lower incidence
of C. difficile in their fecal microbiota compared
with control patients. The incidence of CDI was
low, with only one patient in the control group
developing CDI, while none in the treated
group did so. The authors suggested a potential
role for synbiotics in suppressing overgrowth of
C. difficile after surgery [22]. The literature
search also identified a study reporting the
impact of infection control interventions on
CDI occurrence. A medical record-based C. dif-
ficile-associated disease at a single center was
reported to have an incidence of 0.47 cases/
1000 inpatient days, which fell to 0.11 cases/
1000 patient-days after intensive infection
control intervention [23]. Infection control
measures included carbapenem restriction and
continuous instruction to the ward staff on
infection control measures [23].
Some of the epidemiological reports high-
lighted the incidence and prevalence of CDI in
particular patient groups (Table 1; Fig. 2). For
example, in patients undergoing HSCT, the
cumulative incidence of CDI was 6.2% for all
patients, compared with 9.2% in the allogeneic
HSCT subpopulation, 1.0% in the autologous
HSCT subpopulation and 9% in a cohort of
HSCT recipients who received unrelated cord
blood [24, 25]. In a cohort of liver transplant
patients, CDI-associated diarrhea occurred at a
rate of 4.5% [26]. Among rheumatology inpa-
tients, CDI was observed in 0.16% [27]; in a
large cohort of patients with sepsis, hospital-
acquired CDI was observed in 1.3% of patients
without and 1.4% with ulcer prophylaxis [28]. A
retrospective database review of over 140,000
gastrointestinal (GI) surgery patients reported
CDI (ICD-10 definition) in 0.28% of the study
population, or a prevalence of 2.8 cases/1000
patients [29]. In a smaller cohort study of
patients with active ulcerative colitis, 40.1%
tested positive for possible CDI [30]. A study of
pediatric patients with cancer who were hospi-
talized at a single center reported CDI (clinical
symptoms and positivity for toxin EIA using
TOXA/B QUIK CHEK) in 27% of the study
population [31]. The authors suggested that the
high incidence of CDI compared with other
studies of similar patient populations in non-
Japanese settings may be because of the much
longer length of stay for patients with cancer in
Japan compared with other countries [31].
Among the studies that reported on possible
C. difficile colonization of patient groups was an
epidemiological study of hospitalized pediatric
patients. At least 1 in 10 pediatric patients
Fig. 2 Clostridium difficile infection (defined as diarrhea/
CD toxin) reported in retrospective cohorts of Japanese
patients. CRC colorectal cancer, GI gastrointestinal, HSCT
hematopoietic stem cell transplantation, IBD inflamma-
tory bowel disease, pts patients, RA rheumatoid arthritis.
Patient numbers represent those diagnosed with Clostrid-
ium difficile infection
50 Infect Dis Ther (2018) 7:39–70
harbored C. difficile asymptomatically, while
fecal cytotoxin was found in 9% of otherwise
healthy children and 23.1% of children with
underlying disease [32]. However, these find-
ings should be interpreted with caution as the
inclusion of patients younger than 3 years old
may increase the likelihood that the diarrhea
had a cause other than C. difficile [33].
The reviewed studies included reports of both
hospital and community patients. No papers
were identified that specifically related to
patients in long-term healthcare facilities and
only one paper reported on changes in infection
over time [23]. Therefore, depending on the
patient group and methods used to define and
assess CDI, the incidence varied between 0.8 and
4.71/10,000 patient-days, while the prevalence
was between 0.3 and 5.5 cases/1000 patients.
Risk Factors
Known risk factors for CDI include: co- and
previously administered broad-spectrum
antibiotics; age and comorbidities; poor infec-
tion-control practices; GI tract surgery; and
gastric-acid suppressing agents [13, 34–36].
Thirteen studies in our search, including a large
database study representing 40% of all adult-
care hospitalizations, identified risk factors for
CDI in Japanese patients, which included older
age, higher comorbidity index; gastric acid-
suppressing proton pump inhibitors (PPIs); and
a longer pre-operative LOS before GI surgery
[19, 20, 24–26, 29, 31, 32, 36–40] (Table 1).
Malignant disease and intensive care unit (ICU)
stay were linked with increased risk for CDI
recurrence in in- and outpatients [20]. Six arti-
cles reported on the number of days spent in
hospital prior to surgery or CDI diagnosis,
indicating a wide variation in inpatient stay
before diagnosis [18, 20, 29, 38, 41, 42]. The
only study to formally compare pre-operative
number of days in hospital for patients who did
and did not develop CDI found no difference
between the two patient groups, with a median
(interquartile range) of 6 (3–14) days and 5 (3–8)
days, respectively (p\0.001) [29].
Patients undergoing HSCT are recognized to
be at particular risk of infection. Allogeneic
HSCT, conditioning for HSCT, acute leukemia
and prolonged neutropenia in the first 30 days
after HSCT may all confer an increased risk for
CDI as reported in a single-center study [24]. In
contrast, it was noted that among allogeneic
HSCT patients, treatment with total body irra-
diation may reduce post-transplant risk of CDI
[25].
A study of pediatric patients reported that
tube feeding was significantly associated with
higher colonization rates by toxin-positive
C. difficile [32].
Antibiotic use was a risk factor for C. difficile
diarrhea in a number of studies [19, 31, 37, 38];
however, in a study of liver transplant patients,
the intensity of antibiotic use (measured as use
of preoperative antibiotics or the number of
antibiotics used postoperatively) was not a pre-
dictor for C. difficile diarrhea [26]. Among hos-
pitalized pediatric patients with cancer, use of a
wide variety of antibiotics (the study specified at
least four different types) in the 60 days prior to
CDI diagnosis was a significant risk factor for
the development of CDI [31].
Specific Strains Responsible for CDI
A review of CDI in Asia in 2013 reported that
PCR ribotypes 027 and 078 were rare, while
variant toxin A-/toxin B? strains of ribotype
017 were common. Furthermore, in Japan,
common ribotypes include 014, 002 and 001,
and ribotype smz/018 has been implicated in
widespread disease [3]. The review noted that a
variety of typing techniques has been used in
Japan, including tcdA and tcdB detection, pulsed
field gel electrophoresis (PFGE), PCR ribotyping
and slpA typing. Although molecular typing
had identified toxigenic A-B? strains, the
authors did not comment on binary (CDT)
toxin assessment or C. difficile surveillance in
Japan [3].
In our literature search, 16 papers provided
further details of testing methods used in Japan
and described reports on the isolates and strains
associated with CDI in Japanese cohorts
(Table 2). The methods used to detect CDI and/
or detect, isolate and type C. difficile included
stool culture and C DIFF QUIK CHEK
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COMPLETE; stool culture, PCR ribotyping and
slpA sequence typing; stool culture, PCR and
PFGE; and rRNA-targeted RT-qPCR and multi-
plex PCR for toxin gene profiling. Reported
methods of testing for C. difficile toxins inclu-
ded: toxin A testing by Uniquick (in 2004) [43];
PCR assessment for toxin A, B and CDT genes
[44]; TOX A/B QUIK CHEK [45]; and multiplex
PCR [46]. Rapid detection methods evaluated
and reported in Japan include detection of GDH
and toxin A/B in feces (using Immunocard and
TOX A/B, respectively) [47]; and detection of
GDH and toxin A/B simultaneously using C
DIFF QUIK CHEK COMPLETE [41]. Although
mass spectrometry methods have also been
reported, these were not considered suitable for
typing C. difficile [48].
Our literature review (Table 2) suggests that
most C. difficile isolates associated with infection
in Japan produce both toxins A and B. Available
studies suggest a low prevalence of binary toxin-
positive (CDT?) strains—between 0 and 6.8%
reported across studies [19, 44, 46, 49–51]. A small
study from 2015 found that outbreak and non-
outbreak isolates were predominantly smz/ysmz
(by slpA typing) and that of five binary toxin-
positive strains, one was ribotype 027 and one 078
[51]. Individual papers appear to support the
conclusion that ribotypes 027 and 078 are rare in
Japan [44, 49, 50], and that smz/018, yok, 002,014
and 369 (trf by slpA typing) are common
[3, 42–44, 46, 49–51]. A recently published sub-
study of a global RCT that isolated 54 strains of
toxigenic C. difficile (by EIA/PCR assays) from the
stool cultures of93hospitalizedpatientsat35 sites
in Japan appeared to corroborate this finding [52].
The most common PCR ribotypes were 052 (28%
of isolates), 018 (19% of isolates), 002 (15% of
isolates) and 369 (9% of isolates), and 052 was
considered to be an ‘established’ strain, as it was
widely distributed across Japan. Ribotypes 027
and 078 were not isolated in the substudy [52].
Recurrence
Twelve publications reported on CDI recurrence
(Table 3) [18, 21, 24–26, 31, 39–42, 44], with
rates in studies that included specific definitions
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patients [24] to 27.3% in a cohort of 11 liver
transplant recipients with CDI [26]. The time
period over which recurrence was defined or
assessed varied widely from 14 to 365 days after
the initial CDI episode [18, 21, 24, 25, 31, 44].
One retrospective chart review of 242 liver
transplant recipients, 11 of whom developed
CDI, reported recurrence in 2 of 8 patients who
received vancomycin [26]; no analysis of risk
was made in relation to the choice of treatment
for CDI. A retrospective cohort study based on
chart reviews of hospital-onset CDI cases at four
teaching hospitals found that neither the
severity of CDI nor adherence to clinical prac-
tice guidelines affected the risk of CDI recur-
rence [21]. In a retrospective study, multivariate
analysis identified malignant disease (p = 0.03)
and ICU hospitalization (p = 0.049) as risk fac-
tors for CDI recurrence within 8 weeks of the
previous CDI episode [20]. A systematic review
and meta-analysis of published studies reported
that use of PPIs was significantly associated with
recurrent CDI (pooled OR 1.73, 95% CI
1.39–2.15; p = 0.02) (Table 3) [40].
Healthcare Utilization
A large retrospective chart review of 22,863
patients by Honda et al. reported a median LOS
among 126 CDI cases of 41.5 days (17.5 days
before and 18 days post-CDI diagnosis) [18]. The
sparsity of available LOS data did not allow any
analysis of trends for CDI-related LOS over the
years examined. The adjusted attributable LOS
and costs related to CDI were reported from one
large database study of 143,652 hospitalized
patients [29]. There were 409 cases of CDI with
the infection contributing to a LOS increase of
12.4 days (95% CI 9.7–15.0; p\0.001) and a cost
increase of US$6576 (95% CI 3753–9398;
p\0.001) compared with control patients who
did not develop CDI. However, of note, this
study included patients who had undergone
specific surgical procedures and had CDI identi-
fied using diagnostic codes rather than by diag-
nostic tests [29], which could potentially lead to
inaccurate identification of CDI.
Cases of CDI may require patient transfer to
the ICU. The study by Honda et al. found that
9.5% of 126 CDI cases needed ICU admission
[18]. There were 65 (51.6%) patients who were
classified as having severe CDI, using the
severity assessment score developed by Zar et al.
[53]; three patients (2.4%) underwent CDI-re-
lated colectomy/diverting loop ileostomy
because of critical illness or failure of medical
therapy. Another retrospective chart review
based on stool samples from in- and outpatients
at a single hospital identified 76 patients with
hospital-onset CDI, with three (3.9%) cases
requiring ICU care [20].
Mortality
All-cause mortality within 30 days ranged from
3.4 to 15.1% [18, 20, 21, 29, 39]. Honda et al.
reported that mortality was associated with an
increased Zar severity score [18]. Of note, the
Zar severity criteria will score a patient 1 point
(2 points are defined as severe CDI) based only
on age 60 years or older [53], and the median
age of patients in the Honda et al. study was
78 years [18]. A multicenter retrospective cohort
study of 160 hospitalized patients with CDI
reported 30-day all-cause mortality of 13%, and
found no significant difference between the
mortality rate among patients with severe and
non-severe CDI, or among those whose treat-
ment adhered and did not adhere to clinical
practice guidelines [21]. At 90 days, all-cause
mortality among CDI cases was reported as
14.5% in one retrospective chart review [20].
Hosokawa et al. [25] concluded that, among
patients who underwent unrelated cord blood
transplantation, overall survival at 2 years was
no different for those who developed CDI than
for those who did not (42 vs. 46%, respectively;
p = 0.77). One database study demonstrated
that inpatient mortality was significantly higher
in CDI patients than in those without CDI (3.4
vs. 1.6%; p = 0.008) [29], although the results of
this study should be viewed with caution owing
to the reliance on recorded diagnoses of CDI
from administrative databases (which are less
well validated than those in prospective cohorts
or registries, for example), the inclusion of only
patients undergoing GI surgery, and the loss of
many patients from the propensity score-
64 Infect Dis Ther (2018) 7:39–70
matched analysis. The use of vancomycin was
associated with reduced mortality (OR 0.43;
95% CI 0.25–0.75) in a multicenter, case–con-
trol and cohort study of 1026 CDI patients [39].
DISCUSSION
This systematic literature review identified 55
papers providing insights into the rates of CDI,
patient groups affected and impact of CDI in
Japan. Most of the studies were retrospective
data reviews, and many focused on patients
with suspected CDI, and the rates and preva-
lence of CDI in those groups. Fewer studies
reported overall rates of hospital- and commu-
nity-acquired CDI. Nevertheless, the current
literature suggests that hospital-onset CDI in
Japan occurs at an incidence of 0.8–4.7 cases/
10,000 patient-days; lower than that reported in
Europe for winter 2012–2013 (country range
0.7–28.7/10,000 patient bed-days), and similar
to the US for hospital-onset CDI in 2013 (6.0/
10,000 patient-days for laboratory-identified
CDI and 4.4/10,000 patient-days for traditional
surveillance-detected CDI) [54, 55]. However,
direct comparisons between studies are difficult
owing to differences in design, population size
and detection methods used. The prevalence of
CDI in Japan (0.3–5.5/1000 patient admissions)
was lower than that in a US Veterans Health
Administration (VHA) report from 2014, which
recorded that from October 2010 to June 2012,
CDI prevalence at admission was between 5.3
and 6.9/1000 admissions, in settings where 50%
of hospitals used nucleic acid amplification tests
[56]. An analysis of US VHA data for February
2012 to January 2014 reported a pooled CDI
admission prevalence rate of 0.38/100 admis-
sions [57].
CDI in Japan appears to have similar epi-
demiology to that in South Korea, although
distinct from regions of South Asia [3]. There are
a number of factors that contribute to the
unique epidemiology of CDI in Japan. First, if
testing for CDI is not conducted, this makes
data-gathering on both the rate of testing and
test results difficult. While there is a national
surveillance program for infectious diseases in
Japan, there is no national C. difficile screening
program. Methods of testing are also an
important consideration. Indeed, datasets from
CDI surveillance programs highlight that
country-to-country variations in CDI incidence
largely reflect differences in surveillance meth-
ods and how rigorously CDI is investigated in
testing strategies [54]. This literature review
highlights that testing, typing and laboratory
methods for assessment and diagnosis of CDI
have evolved in Japan in recent years, with new
methods continuing to be evaluated against
established methods. However, some authors
have noted that many reports of CDI epidemi-
ology in Japan have relied on insensitive testing
methods, such as EIA toxin tests [16]. While
more sensitive nucleic acid amplification tests
are recommended in clinical practice guidelines
for the detection of C. difficile [7], these are not
yet subject to reimbursement in Japan and are
therefore not widely used, thus reliance on EIA
remains common in clinical practice. It could
be argued that a low detection frequency, as
seen for CDI toxin tests in stool samples, may in
fact reflect a low disease burden, as demon-
strated by Shimizu et al., who reported that
patients with positive EIA toxin tests in stools
had more severe CDI than those patients with
negative stool toxin tests who then had positive
cultures [41]. It is recognized that CDI is under-
diagnosed in many regions and countries
because of a combination of absence of clinical
suspicion and suboptimal laboratory diagnos-
tics [54]. This may also be the case in Japan,
although no papers in this search specifically
focused on reporting under-diagnosed or mis-
sed CDI cases.
Increased LOS is both a risk factor for, and an
outcome of, CDI [29]. A notable factor in Japan
is the general tendency for a longer LOS com-
pared with many other countries, which may
have an impact on, and thus affect, CDI risk and
rates [58]. Incidence of CDI is typically pre-
sented as per patient-days (i.e. patient-bed days
or inpatient days) and it is important to
understand the differences in overall LOS in
different geographic regions when comparing
incidence data. National statistics from Japan
show that in 2014 mean LOS was 31.9 days for
all patients and 41.7 days in those C 65 years
[59], whereas the comparable 2014 statistics
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from the USA were 4.6 days for all patients (not
restricted to those with CDI), 5.2 days for
patients aged 65–74 years and 5.3 days for those
aged 75 years and over [60]. This suggests that if
follow up was similar between nations, roughly
eight times more patients would be included in
the US study compared with a Japanese study to
yield 10,000 patient-days as the denominator.
Given the lengthy LOS in Japan, as in studies
from other countries, rates of, and risks for, CDI
in Japanese patients are increased by factors
such as older age, presence of comorbidities,
certain clinical/surgical procedures and expo-
sure to drug therapies, including antibiotics [1].
We found that CDI recurrence similarly
depended on a variety of factors, including
clinical circumstances and settings, ranging
from 3.3% in HSCT patients [24] to 27.3% in
liver transplant patients [26]. We found very
few data on risk factors for CDI recurrence, such
as the choice of treatment for initial CDI. One
study identified malignant disease and ICU
hospitalization as risk factors for CDI recurrence
[20], although the broad CIs cited for both
(Table 3) suggest that analysis of risk factors in a
larger population is required. As previously
established [1], one systematic review and meta-
analysis identified in our review revealed a
strong association between PPI use and the risk
for initial and recurrent CDI in both adults and
children [40].
Most CDI cases in Japan are caused by strains
of C. difficile that produce both toxins A and B.
Recent reviews of CDI in Asia, which are sup-
ported by our literature review, showed that
ribotype smz/18 (or 018) predominates in Japan
[3] and that ribotype trf/369 is gaining promi-
nence in the country [61]. Several of the studies
we reviewed confirmed a low prevalence of
ribotypes 027 and 078 in Japan. It has been
postulated that the low prevalence of these
highly virulent strains that cause sporadic out-
breaks in Western countries may account for
the low general incidence of CDI in Japan [21].
Further, we found that recent papers reporting
on CDI strain and ribotype increasingly inclu-
ded a binary toxin assessment, although CDT?
C. difficile was rare in Japan [42, 46].
There are a number of limitations to this
review. Most reports on CDI epidemiology in
Japan included here were based on hospital
cohort data, and were often (in 32 of 55 studies)
single-site reports concerning either inpatients
or patients discharged from hospital to the
community. We did not find papers reporting
on CDI rates in long-term care facilities,
although, given the prolonged LOS reported in
studies in our review, some hospitals may ‘re-
place’ long-term care facilities in some instan-
ces. There was a large degree of heterogeneity in
relation to the definition of initial and recurrent
CDI in the studies included in our review. This
hampered our ability to evaluate the epidemi-
ological data in a consistent manner and
reduced the potential to draw robust conclu-
sions. Although the papers reviewed spanned
more than a 10-year period, there were no data
describing local infection changes over time.
However, we did find sporadic snapshots of CDI
in certain patient subgroups and cohorts. Our
review was further limited by a lack of infor-
mation relating to the rate of CDI testing and
no data on community-associated CDI.
Future studies and surveillance are necessary
to gather data on the numbers and types of
patients affected by, or at risk of, CDI in Japan.
Furthermore, data on the clinical impact of CDI
are important for management and resource
planning, and to ensure optimal patient care
and outcomes.
CONCLUSION
The current literature offers some insights into
the evolving epidemiology of CDI in Japan, yet
highlights a number of unresolved questions.
Notably, heterogeneity in the CDI definitions in
the studies we reviewed limited our ability to
draw robust conclusions. With the availability
of newer diagnostic tools and release of clinical
practice guidelines for CDI, there is a need to
undertake more comprehensive and coordi-
nated studies and surveillance of both CDI cases
and C. difficile isolates to map current trends,
review the impact of infection control mea-
sures, increase knowledge of risk factors, and
more fully understand the extent and impact of
hospital-onset CDI in Japanese patient popula-
tions today.
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